Calogero Claudia, Kusel Merci M H, Van Bever Hugo P S, Sly Peter D
Telethon Institute for Child Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia.
J Paediatr Child Health. 2009 Mar;45(3):139-48. doi: 10.1111/j.1440-1754.2008.01441.x. Epub 2009 Feb 2.
The study aimed to determine how childhood asthma is managed in Western Australia by general practitioners (GPs) and specialist paediatricians.
A questionnaire survey was sent to 992 GPs and specialist paediatricians, asking about practice and preferences regarding maintenance management of childhood asthma and treatment of acute asthma. Questions about asthma in infants, pre-school and school-aged children were asked separately.
The overall response rate was 24.7%, with 188/878 (21.4%) of GPs and 44/62 (71.0%) of paediatricians returning the questionnaire. The decision to start maintenance therapy was generally based on symptom frequency and severity. The first choice for maintenance treatment in all age groups was inhaled corticosteroids (ICS). The second most common treatment varied according to age group, with short-acting beta(2)-agonist (SBA) preferred for infants, montelukast or short-acting beta(2)-agonist for pre-schoolers and combination therapy (ICS + long action beta(2)-agonist) for school-aged children. Objective monitoring of lung function with peak flow or spirometry, was used by 40% of GPs and 59% of paediatricians. Acute asthma was primarily managed with inhaled salbutamol and oral corticosteroids. There were few differences in treatment choice between GPs and paediatricians. Many GPs indicated that they did not treat asthma in infants without specialist consultation.
These data show good compliance by the minority of GPs responding to the survey and by paediatricians practising in Western Australia with current Australian asthma management guidelines. Major differences in treatment preferences between the groups were not detected.
本研究旨在确定西澳大利亚州的全科医生(GP)和儿科专科医生如何管理儿童哮喘。
向992名全科医生和儿科专科医生发送了问卷调查,询问有关儿童哮喘维持治疗管理和急性哮喘治疗的实践及偏好。分别询问了有关婴儿、学龄前儿童和学龄儿童哮喘的问题。
总体回复率为24.7%,878名全科医生中有188名(21.4%)、62名儿科医生中有44名(71.0%)返回了问卷。开始维持治疗的决定通常基于症状频率和严重程度。所有年龄组维持治疗的首选都是吸入性糖皮质激素(ICS)。第二常见的治疗方法因年龄组而异,婴儿首选短效β2受体激动剂(SBA),学龄前儿童首选孟鲁司特或短效β2受体激动剂,学龄儿童首选联合治疗(ICS+长效β2受体激动剂)。40%的全科医生和59%的儿科医生使用峰值流速或肺量计对肺功能进行客观监测。急性哮喘主要采用吸入沙丁胺醇和口服糖皮质激素治疗。全科医生和儿科医生在治疗选择上几乎没有差异。许多全科医生表示,未经专科会诊,他们不会治疗婴儿哮喘。
这些数据表明,参与调查的少数全科医生以及在西澳大利亚州执业的儿科医生对当前澳大利亚哮喘管理指南的依从性良好。未发现两组之间在治疗偏好上有重大差异。